News

Immune’s rare skin disease drug maintains shine

Story in BioWorld by Michael Fitzhugh. Preliminary data on three additional patients enrolled in a small open-label study of Immune Pharmaceuticals Inc.’s bertilimumab, an experimental treatment for the rare…

Delving Deep into Immune Pharmaceuticals’ Diverse Pipeline

Immune Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focusing on the treatment of immuno-inflammatory diseases and cancer. The company has several active clinical programs, led by bertilimumab, a first-in-class, fully human…

Immune Presents Biomarker Data On Ceplene at AACR

A team of researchers from Gothenburg University in Sweden presented data from a Phase 4 study on Ceplene® earlier this week at the American Association for Cancer Research (AACR) Annual Meeting in New Orleans, LA. These data could have…